Results 161 to 170 of about 31,841 (197)

Dapagliflozin modulates plasma lipidomic profile and urinary metabolite excretion in type 2 diabetes. [PDF]

Cardiovasc Diabetol
Pezzica S, Pratesi F, Sabatini S, Carli F, Mengozzi A, Solini A, Gastaldelli A.   +6 more
europepmc   +1 more source

Reversing 20 years of diabetes using the carnivore diet in India: a case report. [PDF]

Clin Nutr Res
Verma A.
europepmc   +1 more source

A case report of Graves' disease combined with pseudohypoaldosteronism type IID in a child. [PDF]

Transl Pediatr
Yao J, Li X, Lu W.
europepmc   +1 more source

Severe burns complicated by EDKA, CDI, and NTIS: A case report and literature review. [PDF]

Medicine (Baltimore)
Yan T, Hu D, Wang N, Lin Z, Li S, Wang M, Wen J, Liu R, Feng Q, Jia J, Shang R, Lin G, Xiao R.   +12 more
europepmc   +1 more source

The probiotic <i>Limosilactobacillus fermentum</i> CECT5716 enhances the antihypertensive response to hydrochlorothiazide in spontaneously hypertensive rats. [PDF]

Gut Microbes
González-Correa C, Miñano S, Moleón J, Toral M, Robles-Vera I, Sánchez M, Jiménez R, Olivares M, Martín-Morales N, O'Valle F, Guerra-Hernández E, Romero M, Gómez-Guzmán M, Duarte J.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Valsartan/Hydrochlorothiazide

Drugs, 1999
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire   +2 more sources

Hydrochlorothiazide

Reactions Weekly, 2022
  +6 more sources

Hydrochlorothiazide

Reactions Weekly, 2019
  +6 more sources

Escitalopram/hydrochlorothiazide/losartan/hydrochlorothiazide

Reactions Weekly, 2020
openaire   +1 more source